Autologous Blood and Marrow Transplantation for Hematologic Malignancy and Selected Solid Tumors.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Busulfan; Carboplatin; Carmustine; Cyclophosphamide; Etoposide; Melphalan; Thiotepa
- Indications Acute myeloid leukaemia; Amyloidosis; Chronic lymphocytic leukaemia; Hodgkin's disease; Multiple myeloma; Neuroblastoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Testicular cancer; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- 22 Apr 2021 Biomarkers information updated
- 23 Sep 2013 Planned end date changed from 1 Apr 2024 to 1 Apr 2022 as reported by ClinicalTrials.gov.
- 11 Jan 2012 Actual patient number is 174 according to ClinicalTrials.gov.